文献速递关节外科

多数当代TKA植入系统符合国际基准生存率标准:美国注册研究证据

Most Contemporary TKA Implant Systems Meet International Benchmark Survivorship Standards: Evidence From a US Registry.
PubMed 文献 · Clin Orthop Relat Res · 2026-04-21

该回顾性队列研究将ISAR IPBWG基准应用于美国某医疗系统全关节置换注册库,评估288,584例初次TKA的45种植入系统。结果显示93%系统获2年基准、88%获5年基准、52%获10年优越基准、50%获15年优越基准,少数系统持续未达基准。

要点

  • 2年基准:93%(42/45)系统达标,覆盖99%的TKA病例。
  • 5年基准:88%(37/42)系统达标,覆盖96%的评估病例。
  • 10年优越基准:52%(13/25)系统达标;15年优越基准:50%(6/12)系统达标。

核心结论

  • 将IPBWG基准应用于美国大型关节置换注册库,可识别中长期翻修表现持续较差、合格或优越的TKA植入系统。
  • 研究支持优先选用符合基准标准的TKA植入系统,并在有可靠中长期表现替代品时重新评估未达基准系统的常规使用。

研究设计与样本

  • 回顾性队列研究,数据来自美国某医疗系统全关节置换注册库,纳入2001年1月1日至2024年12月31日因骨关节炎行初次TKA的288,584例,由605名外科医生在68家机构完成。
  • 每种植入系统(股骨与胫骨部件品牌、各部件固定方式、衬垫稳定性及胫骨衬垫活动度)单独评估,注册记录<250例TKA的系统被排除。
  • 采用Kaplan-Meier估计的1减生存率计算累积翻修率(CPR)及95%CI,应用ISAR IPBWG的2、5、10、15年基准标准。

主要发现

  • 45种TKA植入系统中,93%(42种)获2年基准,代表99%(284,929/288,584)的TKA病例。
  • 42种评估5年基准的系统中,88%(37种)获基准,代表96%(274,056/286,020)的评估病例。
  • 25种考虑10年基准的系统中,52%(13种)获优越基准、16%(4种)获非劣效基准;获优越基准的系统用于91%(204,633/224,619)的合格TKA。
  • 12种评估15年基准的系统中,50%(6种)获优越基准,代表89%(119,871/135,060)的评估病例;42%(5种)获非劣效基准,8%(1种)未获基准。
  • 按性别和年龄分层分析中,相同的植入系统持续未获基准。

关键数值与推荐

  • 2年早期基准:CPR 95%CI下限≤2%时获基准。
  • 5年早期基准:CPR 95%CI下限≤3%时获基准。
  • 10年中期基准:95%CI上限≤5%为优越;≤6%(非劣效界值1%)为非劣效;>6%未获基准。
  • 15年晚期基准:95%CI上限≤6.5%为优越;≤7.8%为非劣效;高于非劣效界值未获基准。
  • 每个时间点需至少250例TKA处于风险中方可获基准。

临床怎么用

  • 临床优先选用符合IPBWG基准标准的TKA植入系统,尤其是10年和15年表现优越的系统。
  • 对有可靠中长期性能替代品的未达基准系统,应重新评估其常规使用。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Benchmarking seeks to evaluate implant survivorship at certain follow-up time points against predetermined standards. The International Society of Arthroplasty Registries (ISAR) International Prosthesis Benchmarking Working Group (IPBWG) developed a predefined set of standards in which receiving a benchmark indicates that an implant has acceptable revision-free survivorship, whereas not receiving a benchmark suggests that the revision rate exceeded these established standards. Although benchmarking of TKA implant systems has been performed in select international countries, applications of benchmarks to TKA systems used in a US-based cohort are lacking. QUESTIONS/PURPOSES: We sought to apply the ISAR IPBWG benchmarking standards to our US-based healthcare system's total joint replacement registry and identify TKA implant systems meeting (1) early 2- and 5-year benchmarks, (2) midpoint 10-year benchmarks, and (3) late 15-year benchmarks. As a secondary aim, we sought to evaluate the consistency of these benchmarks when stratified by patient gender and age. METHODS: Data from our US-based healthcare system's Total Joint Replacement Registry were used to conduct a retrospective cohort study. The registry is well suited for benchmarking analyses because it captures all primary and revision TKAs performed within a closed, longitudinal healthcare system, enabling near-complete outcome tracking and comprehensive implant tracking through barcode-based documentation, with routinely audited administrative and clinical coding. Patient follow-up was 96%, 91%, 85%, and 80% at 2, 5, 10, and 15 years, respectively. Surgeons complete intraoperative registry forms via the electronic health record (EHR) for all TKAs, which are crosschecked against implant information-including manufacturer, implant name, and catalog number-recorded in the EHR via barcode scan and extracted into the registry. Patients are longitudinally followed for revision surgery until healthcare plan termination or death, and all identified revisions are manually validated through chart review. We identified all primary TKAs for osteoarthritis performed from January 1, 2001, through December 31, 2024. The final sample included 288,584 primary TKAs performed by 605 surgeons at 68 facilities. The cohort had a mean ± SD age of 68 ± 9 years, mean ± SD BMI of 31.2 ± 5.5 kg/m 2 , was predominantly women (61% [176,641 of 288,584]), and largely comprised patients with ASA class I to II (59% [171,306 of 288,584]). Each unique implant system, defined as the femoral and tibial component brand, fixation for each component, insert stability, and tibial insert mobility, was evaluated separately; systems with < 250 TKAs recorded into the registry were excluded. All-cause revision incidence during follow-up was evaluated using 1 - the Kaplan-Meier estimate and reported as cumulative percent revision (CPR) and 95% confidence interval (CI). Benchmark standards proposed by the IPBWG were used to evaluate the 2-, 5-, 10-, and 15-year time points; at each time point, at least 250 TKAs had to remain at risk to receive a benchmark. Implant systems received an early benchmark at 2 and 5 years after the primary TKA when the lower bound of the CPR 95% CI was less than or equal to the revision rate benchmark standards of 2% and 3%, respectively. Superiority and noninferiority relative to the benchmark standard were determined for 10-year midpoint and 15-year late benchmarks; the noninferiority margin was set at a 20% higher relative revision rate than the benchmark standard. For the 10-year time point, the system was considered superior when the upper bound of the 95% CI was less than or equal to 5%; when the upper bound of the 95% CI was less than or equal to 6% (20% above the 5% benchmark standard, or a 1% noninferiority margin), the system was considered noninferior; when it was above 6%, the system did not receive a 10-year benchmark. For the 15-year time point, systems with the upper bound of the 95% CI less than or equal to 6.5% were considered superior, and those in which the upper bound was less than or equal to 7.8% were considered noninferior; systems in which the 95% CI was above the noninferiority margin did not receive a benchmark. RESULTS: Of the 45 TKA implant systems evaluated, 93% (42) received a benchmark at 2 years, representing 99% (284,929 of 288,584) of the TKAs included. The three implant systems not receiving a 2-year benchmark included the Smith & Nephew cemented, bicruciate-stabilized, fixed-bearing Journey ™ (n = 889; CPR 3.1 [95% CI 2.1 to 4.5]); the Smith & Nephew cemented, bicruciate-stabilized, fixed-bearing Journey II/Journey (n = 2200; CPR 2.8 [95% CI 2.1 to 3.6]); and the Zimmer Biomet cemented, ultracongruent or anterior-stabilized, fixed-bearing Natural Knee®/Natural Knee II (n = 566; CPR 3.9 [95% CI 2.6 to 5.9]). Of the 42 implant systems evaluated for 5-year benchmarks, 88% (37) received a benchmark, representing 96% (274,056 of 286,020) of the cohort evaluated for this time point. Five implants did not receive a 5-year benchmark: the DePuy cemented, posterior-stabilized, rotating PFC Sigma®/MBT (n = 7899; CPR 3.6 [95% CI 3.2 to 4.0]); the Smith & Nephew cemented, bicruciate-stabilized, fixed-bearing Journey (n = 889; CPR 5.4 [95% CI 4.1 to 7.1]); the Smith & Nephew cemented, bicruciate-stabilized, fixed-bearing Journey II/Journey (n = 2200; CPR 5.1 [95% CI 4.1 to 6.4]); the Zimmer Biomet cemented, cruciate-retaining, fixed-bearing Natural Knee II (n = 410; CPR 4.9 [95% CI 3.2 to 7.7]); and the Zimmer Biomet cemented, ultracongruent or anterior-stabilized, fixed-bearing Natural Knee/Natural Knee II (n = 566; CPR 5.9 [95% CI 4.2 to 8.2]). Of 25 implant systems considered for the 10-year benchmark, 52% (13) of systems received a superior benchmark, and 16% (4) of systems received a noninferior benchmark. Eight implant systems did not receive any 10-year benchmark. Implant systems receiving a superior benchmark were used in 91% (204,633 of 224,619) of the eligible TKAs, whereas implants that did not receive any 10-year benchmark were used in only 3% (6385 of 224,619) of the eligible TKAs. At the 15-year time point, 50% (6 of 12) of the implant systems evaluated received a superior benchmark, representing 89% (119,871 of 135,060) of the cohort evaluated at this time point. Forty-two percent (5) of the implant systems received a noninferior benchmark, and 8% (1) of the systems did not receive a benchmark at the 15-year time point. The same implant systems consistently failed to receive benchmarks at various time points in gender- and age-stratified analyses. CONCLUSION: Applying IPBWG benchmarking to a large US-based arthroplasty registry identified TKA implant systems with consistently inferior, adequate, or superior revision performance at mid- and long-term follow-up. These findings support prioritizing implant systems that meet benchmark standards for primary TKA and reevaluating routine use of implants that fail to achieve benchmarks when alternatives with reliable mid- and long-term performance are available. Future studies integrating benchmarking with risk-adjusted analyses are needed to clarify factors driving implant performance and to strengthen postmarket surveillance. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Son SJ, Sambare TD, Sun H, et al. Most Contemporary TKA Implant Systems Meet International Benchmark Survivorship Standards: Evidence From a US Registry. Clin Orthop Relat Res. 2026. PMID: 42010641. doi:10.1097/CORR.0000000000003946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。